SCM
OBIO icon

Soleus Capital Management’s Orchestra BioMed OBIO Stock Holding History

Soleus Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-60,450
Closed -$1.18M – 106
2023
Q1 		$1.18M Buy
+60,450
New +$700K 0.12% 72

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SFG
SVB Financial Group Dallas, Texas $434K AUM 277.67% 1-Year Est. Return

Soleus Capital Management's OBIO Position: Q2 2023 in Review

Soleus Capital Management sold out of Orchestra BioMed (OBIO) in Q2 2023, closing a stake of 60,450 shares — an estimated $1.18M sold.

Soleus Capital Management first reported a position in OBIO in Q1 2023 and held it in 1 quarter. The position peaked at $1.18M in Q1 2023. 39 funds tracked by Wall St. Rank hold OBIO as of Q2 2023.

  • Soleus Capital Management reported no remaining Orchestra BioMed position as of Q2 2023 after selling out during the quarter.
  • Soleus Capital Management sold 60,450 Orchestra BioMed shares in Q2 2023, an estimated $1.18M.
  • Soleus Capital Management first reported a position in Orchestra BioMed in Q1 2023 and held it in 1 quarter.
  • Soleus Capital Management's Orchestra BioMed position peaked at $1.18M in Q1 2023.
  • 39 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2023.

Based on Soleus Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.